Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers |
Park, Choa
(Department of Biological Sciences, Sookmyung Women's University)
Lee, Yejin (Department of Biological Sciences, Sookmyung Women's University) Je, Soyeon (Department of Biological Sciences, Sookmyung Women's University) Chang, Shengzhi (Department of Biological Sciences, Sookmyung Women's University) Kim, Nayoung (Department of Biological Sciences, Sookmyung Women's University) Jeong, Euna (Research Institute of Women's Health, Sookmyung Women's University) Yoon, Sukjoon (Department of Biological Sciences, Sookmyung Women's University) |
1 | Ali, H., Du, Z., Li, X., Yang, Q., Zhang, Y.C., Wu, M., Li, Y., and Zhang, G. (2015). Identification of suitable reference genes for gene expression studies using quantitative polymerase chain reaction in lung cancer in vitro. Mol. Med. Rep. 11, 3767-3773. DOI |
2 | Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607. DOI |
3 | Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013). The Cancer Genome Atlas Pan-cancer analysis project. Nat. Genet. 45, 1113-1120. DOI |
4 | Carretero, J., Medina, P.P., Pio, R., Montuenga, L.M., and Sanchez-Cespedes, M. (2004). Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 23, 4037-4040. DOI |
5 | Chen, L., Engel, B.E., Welsh, E.A., Yoder, S.J., Brantley, S.G., Chen, D.T., Beg, A.A., Cao, C., Kaye, F.J., Haura, E.B., et al. (2016). A sensitive NanoStringbased assay to score STK11 (LKB1) pathway disruption in lung adenocarcinoma. J. Thorac. Oncol. 11, 838-849. DOI |
6 | Clough, E. and Barrett, T. (2016). The gene expression omnibus database. In Statistical Genomics, E. Mathe and S. Davis, eds. (New York: Humana Press), pp. 93-110. |
7 | Facchinetti, F., Bluthgen, M.V., Tergemina-Clain, G., Faivre, L., Pignon, J.P., Planchard, D., Remon, J., Soria, J.C., Lacroix, L., and Besse, B. (2017). LKB1/STK11 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value. Lung Cancer 112, 62-68. DOI |
8 | Gao, Y., Xiao, Q., Ma, H., Li, L., Liu, J., Feng, Y., Fang, Z., Wu, J., Han, X., Zhang, J., et al. (2010). LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl. Acad. Sci. U. S. A. 107, 18892-18897. DOI |
9 | He, N., Kim, N., Song, M., Park, C., Kim, S., Park, E.Y., Yim, H.Y., Kim, K., Park, J.H., and Kim, K.I. (2014). Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. Mol. Cancer Ther. 13, 2463-2473. DOI |
10 | Gill, R.K., Yang, S.H., Meerzaman, D., Mechanic, L.E., Bowman, E.D., Jeon, H.S., Roy Chowdhuri, S., Shakoori, A., Dracheva, T., Hong, K.M., et al. (2011). Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 30, 3784-3791. DOI |
11 | Ho, J.A., Chang, H.C., Shih, N.Y., Wu, L.C., Chang, Y.F., Chen, C.C., and Chou, C. (2010). Diagnostic detection of human lung cancer-associated antigen using a gold nanoparticle-based electrochemical immunosensor. Anal. Chem. 82, 5944-5950. DOI |
12 | Isgro, M.A., Bottoni, P., and Scatena, R. (2015). Neuron-specific enolase as a biomarker: biochemical and clinical aspects. In Advances in Cancer Biomarkers, R. Scatena, ed. (Dordrecht, The Netherlands: Springer), pp. 125-143. |
13 | Kim, N., Yim, H.Y., He, N., Lee, C.J., Kim, J.H., Choi, J.S., Lee, H.S., Kim, S., Jeong, E., and Song, M. (2016). Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Sci. Rep. 6, 29721. DOI |
14 | Liu, D.W., Chen, S.T., and Liu, H.P. (2005). Choice of endogenous control for gene expression in nonsmall cell lung cancer. Eur. Respir. J. 26, 1002-1008. DOI |
15 | Liu, K.J. and Shih, N.Y. (2007). The role of enolase in tissue invasion and metastasis of pathogens and tumor cells. J. Cancer Mol. 3, 45-48. |
16 | Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., Mok, T.S., Reck, M., Van Schil, P.E., Hellmann, M.D., et al. (2018). Metastatic nonsmall cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl 4), iv192-iv237. DOI |
17 | Lung, J., Chen, K.L., Hung, C.H., Chen, C.C., Hung, M.S., Lin, Y.C., Wu, C.Y., Lee, K.D., Shih, N.Y., and Tsai, Y.H. (2017). In silico-based identification of human -enolase inhibitors to block cancer cell growth metabolically. Drug Des. Devel. Ther. 11, 3281-3290. DOI |
18 | Muller, F.L., Colla, S., Aquilanti, E., Manzo, V.E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., and Nezi, L. (2012). Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337-342. DOI |
19 | Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M.G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016). Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27(Suppl 5), v1-v27. DOI |
20 | Peshavaria, M. and Day, I.N. (1991). Molecular structure of the human muscle-specific enolase gene (ENO3). Biochem. J. 275, 427-433. DOI |
21 | Song, M., Lee, H., Nam, M.H., Jeong, E., Kim, S., Hong, Y., Kim, N., Yim, H.Y., Yoo, Y.J., Kim, J.S., et al. (2017). Loss-of-function screens of druggable targetome against cancer stem-like cells. FASEB J. 31, 625-635. DOI |